Rejuvenate Biomed

  • Home
  • Team
  • News
  • Events
  • Contact
  • Home
  • Team
  • News
  • Events
  • Contact
Home News

News

Clinical Phase 2b strategy endorsed by Advisory Board

Rejuvenate Biomed organized a Clinical Advisory Board meeting to discuss the clinical development of lead candidate RJx-01 in sarcopenia. After a fruitful brainstorming session, the Advisory Board supported the Phase 2b trial design.

LEARN MORE

Groundbreaking clinical trial started

Rejuvenate Biomed started the first clinical trial with RJx-01 in disuse-induced muscle atrophy to evaluate its effect on sarcopenia. This trial marks Rejuvenate’s maturation from a preclinical to clinical-stage company.

LEARN MORE

€15.7 million Series B round secured

This round was led by Rejuveron Life Sciences and Vesalius Biocapital. The funding is being used to accelerate the clinical development of RJx-01.

LEARN MORE

Preclinical data reviewed by Scientific Advisory Board

The SAB concluded that the preclinical data of RJx-01 demonstrate proof-of-principle for sarcopenia, and show potential in multiple other muscle- and non-muscle-related disorders.

LEARN MORE

Dr. Ajit Shetty appointed as Chair of the Board

Rejuvenate Biomed appoints Dr. Ajit Shetty as Chair of the Board of Directors. As a veteran of the life sciences industry, Dr. Shetty will strengthen the business strategy of this ambitious company through both mentorship and connections.

LEARN MORE
  • 1
  • 2
  • 3
  • 4

Rejuvenate Biomed

Rejuvenate Biomed is a science based healthy aging company developing prescription drugs to promote healthy aging.

LETS TALK

Wetenschapspark 13
3590 Diepenbeek
Belgium

View map

Agoralaan Abis
3590 Diepenbeek
Belgium

View map

info@rejuvenatebiomed.com

© Copyright 2017-2021 Rejuvenate Biomed NV. All Right Reserved.
  • Privacy Policy
  • Cookie Policy

This website uses cookies to enhance your browsing experience. More information.